Mithra Reports Full Year 2020 Financial Results

  • Strengthening of the financial resources and balance sheet structure via various funding transactions for an amount of EUR 260 million, diversifying the sources of financing
  • Record cash position of EUR 138.7 million allowing the continuation of our Business Development strategy for Donesta® and R&D projects beyond Women’s Health, notably in Covid-19 treatment
  • Licensing milestones from backlog contracts signed for Estelle® amount to more than EUR 450 million, with more than EUR 300 million cash to still be collected
  • First marketing authorization (MA) obtained for lead asset Estelle® in Canada, with other MA expected in Europe and the United States in the first half of 2021

 Liege, Belgium, 09 March 2021 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the year ended 31 December 2020, prepared in accordance with IFRS.

Mithra to Host Webcast for 2020 Financial Results on 9 March 2021

Liege, Belgium, 04 March 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces that it will host a live webcast on Tuesday, 9 March 2021 at 09:30 CET to present its 2020 financial and operating results.

The live webcast can be accessed on the Mithra website or by clicking here.

To participate to the conference call, please register on this link,

A replay of the webcast will be available on the Mithra investor’s website shortly after the close of the call.

The Board of Directors appoints Leon Van Rompay as CEO ad interim

Liege, Belgium, 4 February 2021 – 7:30 CET – Meeting this Wednesday evening, the Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, heard François Fornieri following his indictment in the context of a file relating to functions he previously held in a company not related to Mithra.

 

Nomination of Christophe Maréchal as interim CEO

Liege, Belgium, 21 January 2021 – 22:00 CET – Meeting this Thursday evening, the Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, took note of the arrest warrant issued against François Fornieri in connection with duties he previously performed in a company not related to Mithra.

Mithra Announces 2021 Financial Calendar

Liege, Belgium, 12 January 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces its financial calendar for 2021 :

  • 9 March 2021 : 2020 Full Year Results
  • 20 April 2021 : 2020 Annual Report
  • 20 May 2021 : Annual General Shareholders Meeting
  • 24 September 2021 : 2021 Interim report

This calendar and all corporate information on the Company (financial statements, events or corporate presentations) is available on the Company’s website in the Investors’ section  (investors.mithra.com).

Mithra announces final terms of its offering of EUR 125 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 20:30 CET – With reference to the two press releases issued on 10 December 2020 at 08:00 and 17:30 CET respectively, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces the final terms of the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”).

Mithra announces placement of EUR 125 million convertible bonds due 2025

  • Placement of EUR 125 million senior unsecured convertible bonds due 17 December 2025 has been completed;
  • The Bonds will bear a coupon of 4.250% per annum;
  • The initial conversion price will be set at a 25.00% premium above the reference price, which will be equal to the volume weighted average price of an ordinary share of Mithra on Euronext Brussels from market open to the close of trading on 10 December 2020 and will be announced by press release after the close of trading on Euronext Brussels today.

Liege, Belgium, 10 December 2020 – 17:30  CET – With reference to the press release issued on 10 December 2020 at 08:00 CET, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces that the offering (the “Offering”) of EUR 125 million senior unsecured convertible bonds due 17 December 2025 (the “Bonds”) has been completed.

Mithra launches an offering of up to EUR 150 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 08:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today the launch of an offering (the “Offering”) of senior unsecured convertible bonds due 17 December 2025 (the “Bonds”), for an initial aggregate principal amount of EUR 125 million with an increase option of up to EUR 25 million to be exercised at the discretion of the Company before pricing.

Creation of a New Share Option Plan in Replacement of the 2018 Share Option Plan

Liege, Belgium, 20 November 2020 – 17:45 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that its board of directors has issued, within the framework of the authorized capital, a new share option plan for its personnel, covering 390,717 share options (the “2020 Share Option Plan”).

Mithra Renews its Board of Directors to Support its Operational Ambitions

Liege, Belgium, 3 November 2020, 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, on the initiative of its outgoing Chairman Marc Coucke,  its intention to renew its Board of Directors in accordance with its Strategic Operating Plan.